Drug Trial Radar · NCT02088073
Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
Last checked: Nov 20, 2026Latest source record: Dec 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
258
Actual
Start
Mar 31, 2014
Primary completion
Aug 31, 2014
Study completion Jan 31, 2015
Sponsor
- Lead sponsor
- ZS Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium levels (3.5 - 5.0 mmol/l, inclusive) among hyperkalemic subjects in whom normokalemia was established during the open-label acute phase versus no difference between each ZS dose (highest to lowest) versus placebo control (null hypothesis).
Conditions
- Hyperkalemia
Interventions
Sodium zirconium cyclosilicateDrug
Sodium zirconium cyclosilicate
PlaceboDrug
Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population).Time frame: 22 Days; Maintenance Phase Days 8 - 29, inclusive.
Locations
46 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Anniston, Alabama
Site not named
Huntsville, Alabama
Site not named
Scottsboro, Alabama
Site not named
Phoenix, Arizona
Site not named
Tempe, Arizona
Site not named
Hawaiian Gardens, California
Site not named
Los Angeles, California
Site not named
Paramount, California
Site not named
Riverside, California
Site not named
Atlantis, Florida
Site not named
Bradenton, Florida
Site not named
Brandon, Florida
Site not named
Brooksville, Florida
Site not named
DeLand, Florida
Site not named
Edgewater, Florida
Site not named
Miami, Florida
Site not named
Miami Lakes, Florida
Site not named
New Smyrna Beach, Florida
Site not named
Ocala, Florida
Site not named
Summerfield, Florida
Site not named
Tampa, Florida
Site not named
Winter Park, Florida
Site not named
Columbus, Georgia
Site not named
Decatur, Georgia
Site not named
Evergreen Park, Illinois
Site not named
Joliet, Illinois
Site not named
Shreveport, Louisiana
Site not named
Auburn, Maine
Site not named
Chesterfield, Michigan
Site not named
Kansas City, Missouri
Site not named
Las Vegas, Nevada
Site not named
Flushing, New York
Site not named
Altoona, Pennsylvania
Site not named
Providence, Rhode Island
Site not named
Orangeburg, South Carolina
Site not named
Sumter, South Carolina
Site not named
Chattanooga, Tennessee
Site not named
San Antonio, Texas
Site not named
Gosford, New South Wales, Australia
Site not named
Woolloongabba, Queensland, Australia
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.